Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2010

View Archived Issues

GDNF gene therapy shows promise in Parkinson's disease model

RAD-1901 is efficacious in phase IIa trial in postmenopausal women

Novel RAF kinase inhibitors emerge from Takeda R&D

First-in-human data presented on MLN-9708 in nonhematologic cancer

Serotonin receptor modulators discovered at Nanotherapeutics

Concert Pharmaceuticals claims new deuterated agents

Kagawa Medical University claims new angiogenesis-promoting agents

GSK claims calcium-sensing CaS receptor ligands

Pardoprunox is effective in PD but dose adjustment is needed

Phase III data detailed for add-on safinamide in PD

Versartis commences phase Ia trial of VRS-859 in type 2 diabetes

Reduced melanoma cell growth observed in in vitro testing of GAP-107B8

AstraZeneca and Targacept begin phase III program for TC-5214 in MDD

Phase I trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Infinity enrolling patients in phase I trial of IPI-493 for hematologic malignancies

First patients enrolled in phase I/II study of PVS-10200 for prevention of restenosis

Cellceutix's KM-391shown to increase serotonin levels in preclinical study

Sanofi-aventis begins phase I trial of anticancer agent SAR-650984

Amorfix and QED to co-develop high-affinity monoclonal antibodies for cancer

Anthera begins enrollment in pivotal phase III study of varespladib

EndoTAG-1 effective in triple receptor-negative breast cancer in phase II trial

Merck receives FDA approval for Dulera for asthma in patients 12 years and older

Santaris and miRagen develop microRNA-targeted cardiovascular medicines

FDA advisory committee meeting scheduled to review Contrave NDA

Sanofi-aventis and Metabolex enter into licensing agreement for novel antidiabetic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...